FF
CPRX

Friedenthal Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Friedenthal Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37,139
Closed -$738K – 278
2024
Q3 		$738K Buy
+37,139
New +$688K 0.43% 77
2023
Q1 		– Sell
-43,151
Closed -$803K – 117
2022
Q4 		$803K Buy
+43,151
New +$664K 0.56% 38

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Friedenthal Financial's CPRX Position: Q4 2024 in Review

Friedenthal Financial sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 37,139 shares — an estimated $738K sold.

Friedenthal Financial first reported a position in CPRX in Q4 2022 and held it in 2 quarters. The position peaked at $803K in Q4 2022. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

  • Friedenthal Financial reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Friedenthal Financial sold 37,139 Catalyst Pharmaceutical shares in Q4 2024, an estimated $738K.
  • Friedenthal Financial first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 2 quarters.
  • Friedenthal Financial's Catalyst Pharmaceutical position peaked at $803K in Q4 2022.
  • 336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Friedenthal Financial's 13F filing for Q4 2024, filed 13 Jan 2025.